ArticleEJNMMI research2026
Identifying genetics biomarkers in correlation with pathological and PSMA PET/CT characteristics in prostate cancer.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is a prevalent disease with diverse tumor characteristics that complicate treatment. The integration of spatial patterns from prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), pathology and expanding genomic data represents a groundbreaking advancement in histo-imaging genomics. The aim of this study was to elucidate the internetwork mapping between genetic biomarkers and PSMA PET/CT imaging in prostate cancer patients.
resultsmRNA sequencing and clinical data from 433 prostate cancer patients were retrieved from The Cancer Genome Atlas (TCGA) database. Differential gene expression between the Gleason score (GS) > 7 and GS ≤ 7 groups was analyzed. Feature selection was performed following the univariate and multivariate logistic regression analyses. A GS predictive model was developed using multivariate logistic regression. Additionally, local samples and images from 27 patients were collected. PSMA PET/CT imaging was performed before radical prostatectomy, and mRNA sequencing of prostate cancer lesions was conducted using next-generation sequencing. Differentially expressed genes identified from the TCGA dataset were subsequently analyzed for correlations with PET-related metrics in the local dataset by utilizing Pearson correlation analysis.Out of the TCGA dataset, 174 genes exhibited differential expression. After feature selection, 53 genes remained. In the local dataset, ten genes (EFNA2, CACNA1I, CA1, MYBPC3, CYP1A1, TLCD3B, LRTM2, GBX2, SPSB4, and GDF3) demonstrated significant associations with PET-related metrics. When comparing the differential expression of genes between the GS>7 and GS≤7 groups, six genes (STMN2, CYP1A1, THRSP, LIPC, GBX2, and SPSB4) in the GS>7 group and eight genes (FBXL16, KLK14, DIRAS2, TERB2, PRAME, UTS2B, UGT2B15, and LINC02798) in the GS≤7 group were significantly correlated with PET-related parameters.
conclusionsThis study identified genetic markers significantly correlated with PSMA PET/CT imaging features in prostate cancer patients. These findings may provide a valuable foundation for optimizing prostate cancer diagnostic procedures and tailoring therapeutic approaches based on genetic and imaging biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.